Biofidelity launches ASPYRE®-Lung reagents, enabling laboratories worldwide to perform rapid precision genomic analysis
06 Dec 2023
ASPYRE-Lung Research Use Only (RUO) reagents enable localized testing and rapid results across all NCCN guideline recommended genes for non-small cell lung cancer (NSCLC).
CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Dec. 6, 2023 /PRNewswire/ -- Biofidelity today announced the commercial launch of its ASPYRE®-Lung RUO reagent product.
ASPYRE-Lung RUO reagents enable localized testing & rapid results across recommended genes for NSCLC
ASPYRE-Lung dramatically simplifies and accelerates the detection of genomic biomarkers, enabling localized testing at a fraction of the cost of current sequencing tests, with results available in days instead of weeks.
Learn more about ASPYRE-Lung RUO here.
"Following the recent launch of the ASPYRE-Lung Laboratory Developed Test (LDT) we are excited to quickly deliver our reagent solution to customers for research use," said Barnaby Balmforth, PhD, Biofidelity Co-founder and CEO. "Both launches represent a major step toward decentralizing genomic testing and enabling enhanced access to critical biomarker testing through our CLIA laboratory and research customers."
ASPYRE-Lung RUO solves key issues that create barriers to biomarker testing. ASPYRE runs on existing PCR instruments already available in laboratories around the world, and can be rapidly implemented without new laboratory staff, sample batching, or complex bioinformatics. ASPYRE's high sensitivity enables testing from tissue samples with as little as 10% tumor content, compared to 20% or 30% for most competing assays. And critically, ASPYRE enables fast analysis of comprehensive panels of genomic biomarkers without the need to send samples to a centralized lab, which often takes weeks to obtain results, allowing labs to maintain control of valuable samples.
Customers are eager to internalize rapid precision diagnostics. "At Athena Esoterix we're honored to serve a diverse group of clients, all of whom require high-quality diagnostic testing with rapid turnaround", said Elizabeth Forrester, PhD, Athena Esoterix Founder and Technical Director. "ASPYRE-Lung RUO will help us enable our physician customers to provide rapid input into their research projects."
About Biofidelity
Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world.
ASPYRE®, the first application of our novel molecular biology technology platform, makes genomic analysis simpler, faster, and more efficient. With the ability to harness existing instrumentation commonplace in laboratories worldwide, ASPYRE provides straightforward, cost-effective access to the vital information needed for accurate targeting and monitoring of cancer treatment.
Visit biofidelity.com and connect on LinkedIn and X.
Contact
Andrea Conners
+1 239-828-1202
media@biofidelity.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.